The upgraded GMP sterile manufacturing capabilities allow the company to handle larger volume commercial aseptic filling of sterile liquids and sterile powders. Later stages of the sterile processing expansion will include additional GMP manufacturing facilities, equipment and automation in order to provide fully integrated sterile manufacturing services from preclinical to commercial production, for both sterile API and finished doses.
”The expansion of our sterile liquid and sterile powder filling capabilities is in response to the requirements of our customers," said Peter Pekos, chief executive officer of Dalton. “These upgraded capabilities not only increase our overall capacity but allow us to offer more complete and efficient sterile manufacturing services. This will allow Dalton to provide more cost effective and flexible support for our client’s aseptic drug development and manufacturing requirements. Future stages of this expansion will add high-value capabilities supporting large and small molecule development, in line with the evolving needs of the sterile manufacturing marketplace.”